1 / 62

Contraception in medical diseases

Contraception in medical diseases. Dr.Prerna kumari Dr.Vatsla Dadhwal Dr.Murali. Contraception. Half of pregnancies are unintended Half of unintended pregnancies result from inconsistent or incorrect contraceptive use Risk of method vs. risk of pregnancy

ulmer
Download Presentation

Contraception in medical diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Contraception in medical diseases Dr.Prerna kumari Dr.Vatsla Dadhwal Dr.Murali

  2. Contraception • Half of pregnancies are unintended • Half of unintended pregnancies result from inconsistent or incorrect contraceptive use • Risk of method vs. risk of pregnancy • What is the most important issuefor the clinician prescribing contraception?

  3. Objectives • Easily access evidence-based recommendations for contraception in women with medical illness • Understand the underlying evidence for these recommendations • Balance the risks of contraception against the risks of pregnancy in these women

  4. WHO Eligibility Criteria for Use of Reversible Contraceptive Method • No restriction • Use the method • Advantages of method outweigh the risks • Generally use the method • Risks outweigh the advantages • Use only if no other method available • Unacceptable health risk if method used • Do not use the method 1 2 3 4 Medical Eligibility Criteria for Contraceptive Use 2009 (www.who.int/reproductive-health)

  5. Sterilization • Accept(A)- There is no medical region to deny sterilization to a person with this condition • Caution(C)-The procedure is normally conducted in a routine setting, but with extra preparation & precautions • Delay(D)-procedure is delayed until the condition is evaluated and/or corrected • Special(S)-Procedure should be undertaken in a well equipped setting. Medical Eligibility Criteria for Contraceptive Use (www.who.int/reproductive-health)

  6. Which patient,Which method?… • Personal characteristics & Reproductive history (Age,Smoking,Obesity,Parity,Postpartum,Postabortion) • Cardiovascular disease • DVT/PE • Neurologic conditions • Endocrine conditions • Gastrointestinal disease • Malignancies • Rheumatologic disease • Reproductive tract disorders and infections • Anemias • Drug interactions

  7. Personal characteristics & Reproductive history • Age- No relation of contraception with age- except in patient ≥40 years-CHC’s- • Menarche to <18 yrs &>45yrs-DMPA/NET-EN- • Menarche to <20yrs(IUD)- Risk of cardiovascular disease increases with age & may also increase with COC use. 2 2 Bone mineraldensity decreases with long term use of DMPA 2 • Risk of expulsion due to nulliparity • Risk of STI’s

  8. SMOKING CHC’S • <35 and smoke: C2 • >35 and smoke <15/day:C3 • >35 and smoke > 15/day: C4 (COC users who smoke are at increased risk for CVD and MI; risk increases with number of cigarettes smoked) POC’S &IUD’Sare safe. Medical Eligibility Criteria for Contraceptive Use (www.who.int/reproductive-health)

  9. Obesity 2 CHC’S BMI > 30kg/m2 • Possible increased risk of VTE, MI, stoke • Inconsistent evidence about body wt and efficacy • NOT more likely to gain • POC’S- C1; C2 <18???NET-EN(Potential effect of NET-EN on bone mineral density) IUD’S- Because of elevated risk for dysfunctional uterine bleeding and endometrial neoplasia, use of levonorgestrel intrauterine system may be a particularly sound choice for obese women 1

  10. Bariatric Surgery(US-MEC) Restrictive procedures: gastric band or sleeve • CHC’S- Malabsorptive procedures • COCs: • Patch/Rings: 1 3 1

  11. Postpartum -Breastfeeding 4 3 CHC’s- < 6weeks postpartum- ≥6weeks to <6 months postpartum- ≥6 months postpartum-C1 POC’S <6 weeks: IUD’s <48hrs-C3 for LNG-IUD (Concern regarding steroid exposure to neonate) >48 hrs to <4weeks-C3 for LNG-IUD &cu-T both Pueperal sepsis- 2 3 4 Medical Eligibility Criteria for Contraceptive Use (www.who.int/reproductive-health)

  12. Postpartum Nonbreastfeeding CHC’S- < 21 days- >21 days- POC’s- Safe IUD’s->48 hrs to<4weeks- 3 Increased risk of thrombosis up to 3 weeks postpartum 1 Increased risk of expulsion 3 Lideggard o et al.Hormonal contraception and risk of venous thromboembolism:national follow up study.British Medical Journal,2009,339

  13. Postabortion Immediately post abortion 1st or 2nd trimester- hormonal contraception- IUD’S- 2nd trimester abortion- Immediate Post septic abortion- Gaffield ME et al.Use of combined oral contraceptivespostabortion.Contraception,2009;80. 1 2 4

  14. CVD: Hypertension CHC’S Adequately controlled/History of hypertension where blood pressure can’t be evaluated: Elevated BP levels: SBP140-159 OR DBP 90-99- SBP > 160 OR DBP > 100- Vascular disease- C4 Hypertension during pregnancy- C2 3 3 4 2 Medical Eligibility Criteria for Contraceptive Use (www.who.int/reproductive-health)

  15. Hypertension Contd……. POC’S Adequately controlled/Elevated BP levels SBP 140-159/DBP 90-99 • POP, I: C1, DMPA: C2 • Implants:C1 SBP >160/DBP > 100 • POP/I: C2, DMPA: C3 • Implants:C2 High BP during pregnancy: C1 IUD’s-cu-C1 LNG-C2 Concern with DMPA: hypoestrogenic states and reduced HDL levels, especially as they persist for a while after discontinuation; not a problem with POPs DVT/PE:no direct evidence exists: POPs and DVT/PE; findings on risk inconsistent Medical Eligibility Criteria for Contraceptive Use (www.who.int/reproductive-health)

  16. ACOG recommends -non-smoking women with blood pressure well controlled by antihypertensive agents, under age 35 and otherwise healthy may try combination hormonal contraceptive methods with careful monitoring; if blood pressure remains controlled, use can be continued. Use of combination hormonal methods in women with severe (ie, uncontrolled) hypertension is contraindicated. Progestin-only methods, barrier methods and IUDs are appropriate options for women with either controlled or uncontrolled hypertension.

  17. DVT/PE • Incidence *Incidence per 100,000 women per year Sulman LP et al.The truth about oral contraceptive and VTE.Journal of reproductive Medicine.2003;48:930-938

  18. CVD: DVT & PE CHC- Hx of DVT/PE NOT on anticoagulant Higher risk of recurrence • Estrogen associated • Pregnancy associated • Idiopathic • Thrombophilia • Cancer • Hx recurrence Lower risk for recurrenc- 4 3 Medical Eligibility Criteria for Contraceptive Use (www.who.int/reproductive-health)

  19. CVD: DVT & PE 4 Acute DVT/PE- DVT/PE on anticoagulant for at least 3 months Higher risk of recurrence- • Thrombophilia • Cancer • Recurrence Lower risk of recurrence- No risk factors 4 3 Medical Eligibility Criteria for Contraceptive Use (www.who.int/reproductive-health)

  20. DVT/PE POC’S- History or acute- On or off anticoagulant/Major surgeries/immobilized/Thrombotic mutations- Family History/ Superficial thrombosis- IUD’s • Cu: • LNG: C2 Acute DVT/PE: C2 both Known thrombogenic mutation- 2 2 1 2 Medical Eligibility Criteria for Contraceptive Use (www.who.int/reproductive-health)

  21. Heart disease

  22. Think? Safety and efficacy both are important. • 1st-whether COC is safe • 2nd-Which POC’s may be recommended • 3rd-whether there is risk of endocarditis/hemodynamic collapse/hematoma formation • Level of contraception desired • Women’s lifestyle • Efficacy of method should also be considered.

  23. Counselling • Must present all the suitable options to the patients. • Benefits and risks of contraception • Risk of pregnancy versus risk of use of contraception.

  24. Heart disease and contraception

  25. Contraception WHO Risk Category 2009

  26. Heart disease &Contraception • Intrauterine devices are not indicated in patients at risk for endocarditis, valvular prostheses, or receiving chronic anticoagulation. • Hormonal contraception :thrombosis -15% in cyanotic patients • Interaction between OCP and anticoagulants (warfarin). • Interaction between Bosentan and POPs. • ?Parenteralcontraception(Mirena) - low profile of complications.

  27. Heart 2006

  28. Heart 2006

  29. IUD’s& pulmonary vascular disease Cardiovascular risk is confined to the time of insertion,in particular to instrumentation of the cervix.vasovagal reaction (5%) may cause potentially fatal cardiovascular collapse in patients with pulmonary vascular disease. To reduce the risk,use of paracervical block / combined spinal & epidural recommended for women with pulmonary vascular disease Implanon is to be preferred Heart 2006;92:Sara Thorne et.al,Risks of contraception and pregnancy in heart disease

  30. Congenital heart disease and conraception

  31. DYSLIPIDEMIA • No need to measure lipid levels prior to prescribing CHC’s unless a woman has known dyslipidemia, other CVD risks (eg, smoking, diabetes, obesity, hypertension), or history of pancreatitis • Oestrogen usually increase HDL and decreases LDL.In contrast progestins decreases HDL and increases LDL & total cholesterol. • Pills containing desogesterol norgestimate & gestodene improve HDL/LDL ratio. Bushnell CD.Oestrogen and stroke :assessment of risk.Lancet neurol.2005;4:743-751

  32. SLE & CONTRACEPTION Positive or unknown antiphospholipid antibodies-CHC-C4,POC-C3,IUD-CU-C1,LNG-C3. Severe thrombocytopenia-CHC-C2,POP-C2,PIC’S-C3,CU-IUD-C3 Immunosuppression- All are C1/2. • ACOG recommends that estrogen-containing contraceptives not be used by women with SLE and a history of vascular disease, nephritis, or presence of antiphospholipid antibodies. Progestin-only methods, barrier methods and IUD are appropriate methods for these women. Culwell KR,Curtis KM et al.Safety of contraceptive method use among women with SLE; Obstetrics and Gynecology ,2009,114.

  33. Neurologic disease CHC’S Headache Not migraines: Initiate: C1 Continue: C2 Migraines: No aura <35 years old Initiate: C2 Continue: C3 > 35 years old Initiate: C3 Continue: C4 Migraines: with aura, Initiate or continue: C4 Any new headache or marked change in Headaches should be evaluated

  34. ACOG guidelines state that CHC’s may be used by women with migraine headaches who do not have focal neurologic symptoms, do not smoke, are otherwise healthy, and are younger than age 35. POC’s are appropriate options for women with migraine with aura who have no other risk factors for stroke (eg, smoking, hypertension). IUDs may be used by women with migraine with or without aura. Barrier methods are preferred in migraine patients with aura

  35. Headache Age<35 Age≥35

  36. Epilepsy 1 CHC’S,POP, IUD-C1 • Watch drug interactions For patient on- phenytoin,carbamazepine,barbiturates,primidone,topiramate,oxcarbamazepine CHC’S & POP’s -C3 DMPA-C1 NE & Implant -C2 IUD’S-C1 Lamotrigine-levels decrease significantly during COC (C3)use and increase significantly during pill free interval but no drug interactions have been reported with POP(C1) use. valproic acid, gabapentin, tiagabine, levetiracetam, vigabatrin and zonisamide does not appear to decrease serum levels of contraceptive steroids in women using combination oral contraceptives Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia, 2005, 46:1414-1417

  37. No evidence that combination hormonal methods increase the frequency of epileptic seizures • use of DMPA has been found to reduce seizure frequency in women with seizure disorders. • Vessey M et.al.Oral contraception and epilepsy: findings in a large cohort study. Contraception 2002;66:77-79

  38. STROKE • CHC’s-C4 • POC’s-POP&Implants-I-C2,C-C3: • DMPA/NE-C3 • IUD’s-CU-C1,LNG-C2 • Sterilization-Caution Concern with LNG IUD and PIC’s lies with theoretical concerns over lipid changes Inconsistent findings on POC and thrombosis

  39. Multiple sclerosis • no progression and possible amelioration of MS during combination hormonal contraceptive use.Progestin-only contraceptive methods, barrier methods and IUDs are also appropriate options for women with MS • Holmqvist P, Wallberg M, Hammar M et al. Symptoms of multiple sclerosis in women in relation to sex steroid exposure. Maturitas 2006;54:149-153

  40. Psychiatric disorders Depressive disorders • Category 1 • No data on bipolar or postpartum disorders • no clinical evidence that concomitant use of combination oral contraceptives and fluoxetine affects the safety or efficacy to either agent • Koke SC, Brown EB, Miner CM. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Am J Obstet Gynecol 2002;187:551-555

  41. VAGINAL BLEEDING

  42. Endocrine disorders CHC’s H/O GDM-C1 Nonvascular disease- non-insulin dependent-C2 insulin dependent-C2 Nephropathy/retinopathy/neuropathy-C3/4 Other vascular disease or diabetes of >20 years duration-C3/4

  43. CHC’s

  44. Combination oral contraceptives • Data is limited to short-term studies • Low-dose estrogen and less androgenic progestins may have less effect on the diabetic control and lipids • No evidence of a negative effect on diabetic sequellae in women with type 1 diabetes • 􀂄 No studies in women with type 2 diabetes Cagnacci A, et alContraception. 2009 Jul;80(1):34-9

  45. POC’s IUD’s H/O GDM-C1 Nonvascular disease- non-insulin dependent/ insulin dependent- CU-C1,LNG-C2 Nephropathy/retinopathy/neuropathy,Other vascular disease or diabetes of >20 years duration- CU-C1,LNG-C2 H/O GDM-C1 Nonvascular disease-C2 Nephropathy/retinopathy/neuropathy- POP& implants -C2,DMPA/NE-C3 Other vascular disease/diabetes of >20 years duration- POP& implants -C2,DMPA/NE-C3 Nelson AL et al.Intermediate –term glucose tolerance in women with history of gestational diabetes :natural history and potential associations with breast feeding and contraception:American journal of Obstetrics &Gynecology,2008;198.

  46. Diabetes Mellutus • progestin-only contraceptives • 􀂄 Injectable DMPA is associated with unfavorable changes in insulin resistance and glucose control • 􀂄 Oral progestin (norethindrone) can be used based on available data • IUD • 􀂄 Levonorgesterel IUD has been avoided due to limited • data, however, recent studies demonstrated its safety • in diabetic women • 􀂄 Copper IUD is metabolically neutral • Rogovskaya S, et al.Obstet Gynecol. 2005 Apr;105(4):811-5. • Xiang AH, et al.Diabetes Care. 2006 Mar;29(3):613-7.

  47. Diabetes ACOG recommends- use of CHC’s in women with diabetes should be limited to non-smoking, otherwise healthy women who are younger than 35 and have no evidence of hypertension, nephropathy, or retinopathy. For women with diabetes, with or without vascular disease or hypertension use of intrauterine contraceptive devices (IUDs) or progestin-only contraceptive methods or barrier methods is not contraindicated.

  48. Gastrointestinal conditions Cirrhosis CHC’S-Mild: C1,Severe: C4 POC’S-Severe-C3 IUD’S- Mild, C1 • Severe: LNG: C3 Cu: C1 Viral Hepatitis CHC’S/POC’S • Acute: C3/4 (with severity) • Chronic/carrier: C1 • IUD-C1 Hormonal contraceptive use has no /minimal effect on chronic hepatitis or its sequelae. Nathelie et al.Effect of hormonal contraceptive use among women with viral hepatitis or cirrhosis of liver;a systematic review. Contraception2009;80:381-386

  49. Gallbladder disease Inflammatory bowel disease (USMEC) CHC’s-Category 2/3 POP, DMPA: C2 Implants: C1 IUD- C1 CHC • Asymptomatic: C2 • Symptomatic-surgery: C2 Medical treatment: C3 POP’S-C2 IUD- Cu: C1 LNG: C2 Cholestasis CHC • Pregnancy related: C2 • COC related: C3 POC’S-COC-related cholestasisC2 Depends on risk for VTE

  50. Malignancies Gestational trophoblastic disease • Decreasing or undetectable beta HCG-IUD’S are C3. • Persistently elevated betaHCG/Malignant disease-IUD’S are C4 CHC’S & POP’s are safe

More Related